People · Operator
Named in public records as an officer, director or promoter · active 2011–2023 · Biotechnology, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Emulate, Inc. | — | Biotechnology | Series C | $182.3M | $1.5B | 2020 |
| Vertos Medical Inc | — | Healthtech | Series C | $177.3M | $514.0M | 2011 |
| Alucent Biomedical, Inc. | — | Biotechnology | Series B | $46.6M | $134.2M | 2015 |
James Corbett at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Corbett on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Myles Greenberg | 2 | 6 |
| Daniel Pelak | 2 | 5 |
| John Ryan | 1 | 17 |
| Andrew Firlik | 1 | 14 |
| Bruce Feuchter | 1 | 12 |
| ERIC MOESSINGER | 1 | 6 |
| Ittai Harel | 1 | 6 |
| Daniel M. Watkins | 1 | 5 |
| Daniel Watkins | 1 | 4 |
| Michael Elliot | 1 | 4 |
| Nick Pappas | 1 | 4 |
| Myles D. Greenberg | 1 | 3 |
| Shlomo Melmed | 1 | 3 |
| Hugo Harrod | 1 | 3 |
| Martin Madaus | 1 | 3 |
| Donald Ingber | 1 | 3 |
| Michael Egholm | 1 | 3 |
| Aaron VanDevender | 1 | 3 |
| Robert Kuhling | 1 | 3 |
| Sharon Kedar | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.